Open Access Open Access  Restricted Access Subscription or Fee Access

Formulation and Characterization of Polyhydroxyalkanoates Copolymer Nanoparticles for Controlled Drug Release

Nupur Ojha, Nilanjana Das

Abstract


The present study was focused on the formulation of polyhydroxyalkanoates copolymer nanoparticles (PHANPs) for in vitro controlled release of the drugs, viz. levofloxacin and amoxicillin. The PHANPs were synthesized by a triple emulsion method and conjugated with amoxicillin and levofloxacin to improve its remedial bioavailability. The PHANPs and drug conjugatedPHANPs were analysed using Scanning Electron Microscopy (SEM), Fourier Transform Infrared (FTIR) spectroscopy and X-Ray Diffraction (XRD). The cell viability % of PHANPs, amoxicillin-conjugated and levofloxacin-conjugated PHANPs on HEK293 cells at a concentration of 400 µg/ml were found to be 90±1.0%, 92±1.0% and 91.26±1.4% respectively, which confirmed that PHANPs are biocompatible and can be used for biomedical applications without any cytotoxic effect. A significant increase in the zone of inhibition was observed on increasing the concentration of drug conjugated PHANPs against E. coli and S. aureus. The in vitro drug delivery study showed controlled release of amoxicillin (99.75±0.1%) and levofloxacin (99.63±0.2%) upto 22 h.


Keywords


polyhydroxyalkanoates copolymer nanoparticles, amoxicillin-conjugated PHA nanoparticles, levofloxacin-conjugated PHA nanoparticles, antibacterial activity, biocompatibility test, in vitro drug release, characterization

Full Text:

PDF

References


Yamamoto H, Kuno Y, Sugimoto S, Takeuchi H, Kawashima Y. (2005). Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions.J. Control. Release. Vol. 102, pp. 373–381.

Lopes-de-Campos D, Pinto RM, Lima SAC, Santos T, Sarmento B, Nunes C, Reis S. (2019). Delivering amoxicillin at the infection site–a rational design through lipid nanoparticles.Int. J Nanomedicine. Vol. 14, p. 2781.

Nachiyar CV, Devi AB,Namasivayam SKR, Rabel AM. (2015). Levofloxacin conjugated polyhydroxybutyrate nanodrug conjugate for in-vitro controlled drug release.Res. J. Pharm. Biol. Chem. Sci. Vol.6, pp. 116–119.

Gevariya H, Gami S, Patel N. (2011). Formulation and characterization of levofloxacin-conjugated biodegradable nanoparticles.Asian J. Pharmacol. Vol.5, pp. 114.

Namasivayam SKR, Robin AG, Bharani RA, Vigneshwaraprakash L, Vivek JM. (2013). Biocompatible polymer gum acacia coated bovine serum albumin (BSA) nanoparticles incorporated azithromycin (P-BSA NP-AZ) preparation for the improved anti-bacterial activity against human pathogenic bacteria.World J. Pharm. Sci. Vol.2, pp. 3094–3106.

Stebbins ND, Ouimet MA,UhrichKE. (2014). Antibiotic-containing polymers for localized, sustained drug delivery. Adv. Drug Deliv. Rev. Vol.78, pp. 77–87.

XiongYC, Yao YC, Zhan XY, Chen GQ. (2010). Application of polyhydroxyalkanoates nanoparticles as intracellular sustained drug-release vectors.J Biomater. Sci. Polym. Ed. Vol.21, pp. 127–140.

Shrivastav A, Kim HY, Kim YR. (2013). Advances in the applications of polyhydroxyalkanoate nanoparticles for novel drug delivery system.BioMed. Res. Int. Vol. 1

Ojha N, Das N. (2018). A Statistical approach to optimize the production of Polyhydroxyalkanoates from Wickerhamomyces anomalus VIT-NN01 using response surface methodology.Int. J. Biol. Macromol. Vol. 107, pp. 2157–2170.

Nobes GAR, Marchessault RH, Maysinger D. (1998). Polyhydroxyalkanoates: materials for delivery systems.Drug Deliv. Vol. 5, pp. 167–177.

Orts WJ,Nobes GAR, Kawada J, Nguyen S, Yu GE, Ravenelle F. (2008). Poly(hydroxyalkanoates): biorefinery polymers with a whole range of applications. The work of Robert H. Marchessault.Can. J Chem. Vol. 86, pp. 628–640.

Gangrade N, Price JC. (1991). Poly(hydroxybutyrate-hydroxyvalerate) microspheres containing progesterone: preparation, morphology and release properties. J Microencapsul. Vol. 8, pp. 185–202.

Gould PL, Holland SJ, Tighe, BJ. (1987). Polymers for biodegradable medical devices. IV. Hydroxybutyrate-valerate copolymers as non-disintegrating matrices for controlled release oral dosage forms.Int. J Pharm. Vol. 38, pp. 231–237.

Gursel I, Yagmurlu F, Korkusuz F, Hasirci V. (2002). In vitro antibiotic release from poly(3-hydroxybutyrate-co-3-hydroxyvalerate) rods.J Microencapsul. Vol. 19, pp. 153–164.

Nwinyi OC, Owolabi TA. (2019). Scanning electron microscopy and Fourier transmission analysis of polyhydroxyalkanoates isolated from bacteria species from abattoir in Ota, Nigeria.J. King Saud Univ. Sci. Vol. 31, pp.285–298.

Ojha N, Das N. (2017). Optimization and characterization of polyhydroxyalkanoates and its copolymers synthesized by isolated yeasts.RJPT, Vol. 10, pp. 861.

Hu YJ, Wei X, Zhao W, Liu YS, Chen GQ. (2009). Biocompatibility of poly (3-hydroxybutyrate-co-3-hydroxyvalerate-co-3-hydroxyhexanoate) with bone marrow mesenchymal stem cells.Actabiomater. Vol.5, pp. 1115–1125.

De Rooy SL,WahyuniETO, Wiratni W,Syamsiah S, Ismail J. (2010). Purification and characterization of poly-hydroxybutyrate (PHB) in Cupriavidus necator.Indones. J Chem. Vol.7, pp. 243–248.




DOI: https://doi.org/10.37628/ijn.v5i2.636

Refbacks

  • There are currently no refbacks.